艾司氯胺酮单药治疗成人难治性抑郁症:一项随机临床试验
这项4期双盲安慰剂对照随机临床试验在美国51个门诊中心纳入378例无精神病性特征的难治性抑郁症成人患者,评估鼻内艾司氯胺酮单药(56 mg或84 mg,每周两次,共4周)的疗效与安全性。第28天时,56 mg和84 mg组MADRS评分较基线的改善均显著优于安慰剂,最常见不良事件为恶心、解离、头晕和头痛。
要点
- 艾司氯胺酮单药56 mg和84 mg在第28天均显著改善难治性抑郁症的抑郁症状。
- 第2天(首剂后约24小时)两个剂量组即显示出显著优于安慰剂的组间差异。
- 常见治疗中出现的不良事件包括恶心、解离、头晕和头痛。
核心结论
- 鼻内艾司氯胺酮单药治疗可能为难治性抑郁症成人患者扩展治疗选择,针对口服抗抑郁药耐受性受限和无应答的未满足需求。
研究设计与样本
- 纳入符合DSM-5重性抑郁障碍标准、无精神病性特征、当前抑郁发作对2种或以上口服抗抑郁药应答不足(改善≤25%)的成人患者。
- 经过2周或更长的无抗抑郁药期后,参与者按1:1:2比例随机接受固定剂量鼻内艾司氯胺酮56 mg、84 mg或匹配鼻内安慰剂,每周两次,共4周。
- 378例符合随机前MADRS严重度标准的参与者接受了至少1次研究药物剂量:艾司氯胺酮56 mg组86例、84 mg组95例、安慰剂组197例。
主要发现
- 第28天,艾司氯胺酮56 mg组与安慰剂的LS均值差异(SE)为-5.1(1.42)(95% CI,-7.91至-2.33),84 mg组为-6.8(1.38)(95% CI,-9.48至-4.07),两组双侧P均<.001。
- 56 mg和84 mg剂量组的观察效应量分别为0.48和0.63。
- 第2天(首剂后约24小时),56 mg组组间差异为-3.8(1.29)(95% CI,-6.29至-1.22;双侧P=.004),84 mg组为-3.4(1.24)(95% CI,-5.89至-1.00;双侧P=.006)。
- 艾司氯胺酮合并剂量组最常见的治疗中出现的不良事件为恶心(56例[24.8%])、解离(55例[24.3%])、头晕(49例[21.7%])和头痛(43例[19.0%])。
关键数值与推荐
- 主要疗效终点为基线至第28天MADRS评分变化,关键次要疗效终点为基线至首剂后24小时(第2天)的MADRS评分变化。
- 参与者基线平均(范围)MADRS总分为37.3(28-50),平均(SD)年龄为45.4(14.1)岁,女性231例(61.1%)。
临床怎么用
- 对于对多种口服抗抑郁药应答不足且存在耐受性顾虑的难治性抑郁症成人患者,鼻内艾司氯胺酮单药可作为考虑选项。
- 用药期间需监测恶心、解离、头晕和头痛等常见不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Esketamine nasal spray, administered in conjunction with an oral antidepressant, is approved for treatment-resistant depression (TRD). However, the efficacy of esketamine nasal spray administered as monotherapy for patients with TRD has not yet been evaluated. OBJECTIVE: To assess the efficacy and safety of esketamine monotherapy compared to placebo in reducing depressive symptoms in patients with TRD. DESIGN, SETTING, AND PARTICIPANTS: This phase 4, double-blind, placebo-controlled randomized clinical trial was conducted from November 2020 to January 2024 at 51 outpatient centers in the US. Adults with major depressive disorder (DSM-5 criteria) without psychotic features who experienced inadequate response (≤25% improvement) to 2 or more oral antidepressants during the current depressive episode were eligible for inclusion. Data analyses were conducted from March 1, 2024, to July 8, 2024. INTERVENTIONS: After a 2-week or longer antidepressant-free period, participants were randomized at a 1:1:2 ratio to fixed-dose intranasal esketamine (56 mg or 84 mg) or matching intranasal placebo, administered twice weekly for 4 weeks. MAIN OUTCOMES AND MEASURES: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to day 28 (primary efficacy end point) and to 24 hours post-first dose (day 2; key secondary efficacy end point) were analyzed by a mixed-effects model using repeated measures. RESULTS: In this multicenter randomized clinical trial, 378 participants who met prerandomization MADRS severity criteria received 1 or more study drug doses (esketamine, 56 mg [n = 86]; esketamine, 84 mg [n = 95]; or placebo [n = 197]). Mean (SD) participant age was 45.4 (14.1) years, 231 participants (61.1%) were female, and baseline mean (range) MADRS total score was 37.3 (28-50). At day 28, the least-square (LS) mean difference (SE) between esketamine and placebo was -5.1 (1.42) (95% CI, -7.91 to -2.33) for the 56-mg dose and -6.8 (1.38) (95% CI, -9.48 to -4.07) for the 84-mg dose (for each, 2-sided P < .001). Observed effect sizes were 0.48 and 0.63 for the 56-mg and 84-mg dose groups, respectively. At day 2 (approximately 24 hours post-first dose), the between-group difference was significant for both esketamine doses: -3.8 (1.29) (95% CI, -6.29 to -1.22; 2-sided P = .004) for 56 mg and -3.4 (1.24) (95% CI, -5.89 to -1.00; 2-sided P = .006) for 84 mg. The most common treatment-emergent adverse events reported for esketamine (combined doses) were nausea (56 participants [24.8%]), dissociation (55 [24.3%]), dizziness (49 [21.7%]), and headache (43 [19.0%]). CONCLUSIONS AND RELEVANCE: According to results of this multicenter, double-blind randomized clinical trial, esketamine monotherapy may expand treatment options for adult patients with TRD by addressing an unmet need of patients experiencing treatment-limiting tolerability concerns and nonresponse with oral antidepressants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04599855.
引用
- Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40601310. doi:10.1001/jamapsychiatry.2025.1317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。